Background Treatment of drug susceptible tuberculosis (DS-TB) requires regimens
containing first line drugs (FLDs') whereas drug resistant tuberculosis (DR-TB) are treated …

Covering: 2016 to 2022 RNA polymerase (RNAP) is the central enzyme in bacterial gene
expression representing an attractive and validated target for antibiotics. Two well-known …

Background & objectives: Antituberculosis (anti-TB) drug induced hepatotoxicity (DIH) is the
most common side effect leading to interruption of therapy. Wide variations have been found …

Background: Antituberculosis drugs cause hepatotoxicity in some individuals leading to
acute liver failure, which results in death. Such phenomena limit the clinical use of drugs …

In our days, tuberculosis, whet ever its localization, became a curable disease. The
cornerstone is a 6 month course of isoniazid, rifampicine and pyrazinamide. All of the three …

Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Background Antituberculosis drug-induced liver injury (ATDILI) is a significant problem of
tuberculosis treatment. This systematic review and meta‑analysis aimed at evaluating the …

Patients with tuberculosis (TB) disease treated with multi‐drug regimens are at risk of
developing drug induced liver injury (DILI), and DILI risk might be even higher in patients …

Adverse drug reactions (ADRs) to first-line anti-tuberculosis drugs are common and may
cause associated morbidity and even mortality if not recognized early. 1, 2, 3 The overall …

Background To assess and compare the prevalence, severity and prognosis of anti-TB drug
induced hepatotoxicity (DIH) in HIV positive and HIV negative tuberculosis (TB) patients in …